Emoxipin, 10 mg/ml 1 ml 10 pcs

Methylethylpyridinol

Indications

– Subconjunctival and intraocular hemorrhage of various origins;

– Angioretinopathy (including diabetic retinopathy);

– Central and peripheral chorioretinal dystrophy;

– Thrombosis of the central retinal vein and its branches;

– Complications of myopia;

– Angiosclerotic macular degeneration (dry form);

– Surgical interventions on the eyes, condition after surgery for glaucoma with choroidal detachment;

– Dystrophic diseases of the cornea;

– Trauma, inflammation and burn of the cornea;

– Protection of the cornea (when wearing contact lenses) and retina from exposure to high-intensity light (laser and sunburn, during laser coagulation).

Pharmacological effect

Pharmacotherapeutic group: Antioxidant

Pharmacological action
Methylethylpyridinol inhibits platelet aggregation, reduces the overall coagulation index, and lengthens blood clotting time. Strengthens the process of fibrinolysis. Reduces blood viscosity, reduces the permeability of the vascular wall. Stabilizes the membranes of blood vessel cells and red blood cells, increases the resistance of red blood cells to mechanical injury and hemolysis. Has angioprotective properties. Improves microcirculation. Effectively inhibits free radical oxidation of biomembrane lipids and increases the activity of antioxidant enzymes. Stabilizes cytochrome P450 and has an antitoxic effect. In extreme situations, accompanied by increased lipid peroxidation and hypoxia, it optimizes bioenergetic processes.

Increases the brain’s resistance to hypoxia and ischemia. In case of cerebral circulation disorders (ischemic and hemorrhagic), it helps to correct dysfunctions of the peripheral nervous system, facilitates the restoration of integrative brain activity, and improves mnestic functions.

Dilates coronary vessels, reduces ischemic damage to the myocardium. In case of myocardial infarction, it limits the size of the necrosis focus, accelerates reparative processes, and helps normalize myocardial metabolism. It has a beneficial effect on the clinical course of myocardial infarction, reducing the incidence of acute heart failure. Helps regulate the redox system in case of circulatory failure.

It has retinoprotective properties, protects the retina from the damaging effects of high-intensity light, promotes the resorption of intraocular hemorrhages, and improves microcirculation of the eye.

Pharmacokinetics
When administered intravenously at a dose of 10 mg/kg, T1/2 is 18 minutes; total clearance – 0.2 l/min; Vd – 5.2 l. It quickly penetrates into organs and tissues, where it is deposited and metabolized. Five metabolites of methylethylpyridinol were discovered, represented by dealkylated and conjugated products of its transformation. Metabolites of methylethylpyridinol are excreted by the kidneys. 2-ethyl-6-methyl-3-hydroxypyridine phosphate is found in significant quantities in the liver.

With retrobulbar administration, methylethylpyridinol appears in the blood almost instantly; During the first two hours, its concentration decreases sharply and after 24 hours the active substance is absent in the blood. In eye tissues, the concentration of methylethylpyridinol is higher than in blood serum.

Special instructions

Treatment should be carried out under the control of blood pressure and blood clotting.

Active ingredient

Methylethylpyridinol

Composition

1 ml of solution contains:

Active ingredient: methylethylpyridinol hydrochloride, (emoxipine) – 10.00 mg.

Excipients: 0.1 M hydrochloric solution: acids – 0.02 ml, water for injection – up to 1 ml.

Contraindications

– Increased individual sensitivity to the drug;

– Pregnancy, lactation;

– Children under 18 years of age.

Side Effects

Short-term excitement, drowsiness, increased blood pressure, allergic reactions (skin rashes, etc.), local reactions – pain, burning, itching, hyperemia, hardening of the periorbital tissues (dissolves on its own).

Interaction

Pharmaceutically incompatible with other drugs.

Storage conditions

In a place protected from light, at a temperature not exceeding 25 ° C.

Keep out of the reach of children.

Shelf life

3 years.

The drug cannot be used after the expiration date.

Manufacturer

Moscow Endocrine Plant, Russia